0
0
MUMBAI – In a significant legal development for India’s pharmaceutical sector, the Bombay High Court has ruled that the National Pharmaceutical Pricing Authority (NPPA) cannot impose ceiling prices on drug formulations that are not explicitly listed in the government’s primary price-control schedule.
The judgment, pronounced on April 10, 2026, by a Division Bench of Justice Manish Pitale and Justice Shreeram V. Shirsat, clarifies that the “ceiling price” mechanism under the Drugs (Prices Control) Order, 2013 (DPCO 2013) is strictly reserved for “scheduled formulations.” For all other medicines—categorized as “non-scheduled”—the regulator’s power is limited to monitoring and capping annual price increases at 10%.
This decision effectively quashes several demand notices issued by the NPPA against pharmaceutical companies for allegedly overcharging on advanced drug variants. The ruling is expected to have far-reaching implications for drug affordability, patient choices, and the regulatory strategy of the Indian government.
The Core Conflict: Scheduled vs. Non-Scheduled
At the heart of the dispute is the classification system used by India to manage medicine costs. The DPCO 2013 contains a First Schedule, which lists essential medicines (derived from the National List of Essential Medicines, or NLEM) that are subject to strict price caps.
The NPPA had argued that if a base drug (e.g., Metformin) is listed in the Schedule, all its variants—including advanced delivery systems like Sustained Release (SR) or Controlled Release (CR) versions—should also fall under the price ceiling. However, the court rejected this interpretation.
“Unless a formulation is specifically included in the First Schedule or added through a notified order, it cannot be subjected to a price ceiling,” the Court stated.
The Bench noted that the government has the power to add these variants to the Schedule through formal notifications. The fact that it chose not to do so for specific advanced formulations suggests a “conscious decision” to keep them in the non-scheduled category.
Why the Ruling Matters for Patients and Doctors
For the average consumer, this ruling highlights a nuanced aspect of the pharmacy counter: not all versions of the same medicine are regulated the same way.
-
Scheduled Medicines: These have a “Ceiling Price” set by the government. Prices are usually lower and very stable.
-
Non-Scheduled Medicines: Manufacturers set the Maximum Retail Price (MRP). While they cannot increase the price by more than 10% in a 12-month period, the starting price can be significantly higher than the scheduled version of the same drug.
Healthcare professionals often prescribe SR or CR variants because they release the medication slowly into the bloodstream, reducing the number of pills a patient needs to take daily and potentially lowering side effects. Under this ruling, these “user-friendly” versions may remain more expensive than their conventional counterparts.
Perspectives: Innovation vs. Affordability
The pharmaceutical industry has welcomed the judgment as a win for innovation. Companies argue that developing advanced delivery systems involves higher research and manufacturing costs that a generic “ceiling price” does not account for.
“Advanced dosage forms like SR and CR formulations offer distinct therapeutic advantages,” noted a recent industry brief. “Treating them the same as older, conventional drugs could discourage companies from launching better versions of essential medicines in India.”
However, public health advocates express concern that the ruling creates a “loophole.” K.M. Gopakumar, a legal advisor and public health advocate, warned that companies might move away from manufacturing basic, price-controlled versions of drugs in favor of slightly modified “advanced” versions to escape price caps.
Regulatory and Statistical Context
The NPPA remains a vigorous enforcer of pricing rules. According to government data shared in Parliament, the regulator recovered ₹72.73 crore from defaulting companies in 2023-24 alone for overcharging. Even with this ruling, the NPPA still monitors over 98,000 medicines via its Pharma Sahi Daam app to ensure that non-scheduled drugs do not exceed the 10% annual price hike limit.
| Metric | Scheduled Formulations | Non-Scheduled Formulations |
| Pricing Rule | Fixed Ceiling Price | Market-determined MRP |
| Increase Limit | Annual WPI-linked adjustment | Max 10% increase per year |
| Oversight | Strict price control | Price monitoring |
What Should Consumers Do?
Patients arhttps://medicaldialogues.in/news/industry/pharma/nppa-cannot-fix-prices-for-non-scheduled-formulations-under-dpco-bombay-hc-168802e advised not to make any changes to their prescriptions based on this legal news. If the cost of a specific “Sustained Release” or “Controlled Release” variant becomes a burden, patients should:
-
Consult their physician: Ask if a conventional, scheduled version of the drug is an appropriate clinical substitute.
-
Verify prices: Use tools like the NPPA’s Pharma Sahi Daam app to check if they are being charged the correct MRP.
-
Ask the pharmacist: Check if there are other brands of the same formulation that might be more affordable.
While the Bombay High Court has narrowed the NPPA’s reach, the ruling also places the ball back in the government’s court. Policymakers may now choose to issue new notifications to explicitly include more advanced variants in the First Schedule, ensuring that “essential” remains synonymous with “affordable.”
References
- https://medicaldialogues.in/news/industry/pharma/nppa-cannot-fix-prices-for-non-scheduled-formulations-under-dpco-bombay-hc-168802
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
